Biomarkers in medicine explores the translation of biomarkers into regulatory science

November 18, 2015

Biomarkers in Medicine, a leading MEDLINE-indexed journal, has published a special focus issue exploring the increasingly important role of biomarkers in both drug development and regulatory decision making. Biomarkers in Medicine is published by Future Science Group.

The special focus issue is guest edited by William Slikker (Director of the FDA's National Center for Toxicology Research, USA) and Huixiao Hong (also of FDA's NCTR). The editors open the issue with a scene-setting foreword which explains, "the motivation behind this issue of Biomarkers in Medicine is to provide a contemporary summary of advances in the translation of biomarkers into regulatory science."

The special issue includes original research, review articles and editorials focused on developments in biomarker research in regulatory science. Articles review the latest advances across a broad range of biomarkers, including miRNA, transcriptomic markers and mechanism-based markers.

Biomarkers, the physical, functional or biochemical indicators of physiological or disease processes, can provide vital information in disease prognosis, in predicting response to therapies, adverse events and drug interactions, and in establishing baseline risk. Biomarkers are being used to develop new predictive, diagnostic and prognostic products, and are playing an increasingly important role in the discovery and development of new drugs.

"I am delighted to have worked with experts from the FDA and numerous other institutions to produce a timely and comprehensive special focus issue discussing the latest advances and next steps for biomarker translation in regulatory science," stated Hannah Wilson, Managing Commissioning Editor of Biomarkers in Medicine.

Biomarkers in Medicine is a peer-reviewed, online and print journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal aims to facilitate translation of research knowledge into the clinic to increase the effectiveness of medical practice.
-end-
To read the full issue, please click here - http://www.futuremedicine.com/toc/bmm/9/11

About Future Science Group

Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological and scientific research. FSG's portfolio includes two imprints, Future Science and Future Medicine. Both publish eBooks and journals. In addition to this core publishing business FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine.

The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards. http://www.future-science-group.com

Future Science Group

Related Biomarkers Articles from Brightsurf:

Urgent need for blood-based biomarkers to diagnosis concussion
There is an urgent need for objective markers for diagnosing concussion, or mild traumatic brain injury.

Engineered bacteria churn out cancer biomarkers
A Cornell lab has created these very tools by commandeering simple, single-celled microorganisms - namely E. coli bacteria - and engineering them to explore the complex process of glycosylation and the functional role that protein-linked glycans play in health and disease.

Exercise induces secretion of biomarkers into sweat
The aim was to reveal the potential of microRNAs in sweat extracellular vesicles in monitoring exercise performance.

Phosphoprotein biomarkers to guide cancer therapy are identified
Researchers led by James Bibb, Ph.D., professor of surgery at the University of Alabama at Birmingham, suggest using a broader lens of post-translational modification analysis to identify new biomarkers of cancer drivers that may allow a much more precise prediction of patient responses to treatments.

Exhaled biomarkers can reveal lung disease
Using specialized nanoparticles, MIT engineers have developed a way to diagnose pneumonia or other lung diseases by analyzing the breath exhaled by the patient.

Race-specific lupus nephritis biomarkers
A University of Houston biomedical researcher has discovered a difference in urinary biomarker proteins of lupus nephritis in patients according to race.

Semen miRNAs could be non-invasive biomarkers for prostate cancer
Researchers of the Human Molecular Genetics group at the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr.

Scientists have found longevity biomarkers
An international group of scientists studied the effects of 17 different lifespan-extending interventions on gene activity in mice and discovered genetic biomarkers of longevity.

After concussion, biomarkers in the blood may help predict recovery time
A study of high school and college football players suggests that biomarkers in the blood may have potential use in identifying which players are more likely to need a longer recovery time after concussion, according to a study published in the July 3, 2019, online issue of Neurology, the medical journal of the American Academy of Neurology.

3D-printed device detects biomarkers of preterm birth
Preterm birth (PTB) -- defined as birth before the 37th week of gestation -- is the leading complication of pregnancy.

Read More: Biomarkers News and Biomarkers Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.